Maria R Fernando1, Mark A Giembycz2, Derek M McKay1. 1. Gastrointestinal Research Group and Inflammation Research Network. 2. Airways Inflammation Research Group, Department of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Abstract
BACKGROUND AND PURPOSE: Alternatively activated macrophages (AAMs) are important cells in the resolution of inflammation and tissue repair. We examined the impact of myofibroblasts, a vital cell in wound healing and tissue repair, on the development and function of AAMs. EXPERIMENTAL APPROACH: The interaction between AAMs and myofibroblasts was tested using conditioned medium from murine dermal myofibroblasts and bone marrow-derived macrophages. AAMs were differentiated with IL-4 and IL-13. KEY RESULTS: Conditioned medium from myofibroblasts enhanced the expression of AAM markers, arginase 1 and Ym1 (chitinase-3-like 3) and the spontaneous production of IL-10, while suppressing LPS-induced nitric oxide production. IL-6 from the myofibroblasts contributed to the amplification of the AAM phenotype; the selective COX-2 inhibitor, NS-398, significantly reduced the ability of myofibroblasts to promote an AAM phenotype. Pharmacological analyses indicated that myofibroblast-derived IL-6 enhanced arginase activity and spontaneous IL-10 output, while PGE2 , via the EP4 receptor, enhanced arginase expression and LPS-evoked IL-10 production. PGD2 suppressed LPS-evoked nitric oxide via the DP1 receptor. Reciprocally, conditioned medium from macrophages treated with IL-4 + IL-13 and myofibroblast conditioned medium components, but not macrophages given IL-4 + IL-13 only, reduced myofibroblast migration, the expression of COX-2, and the production of PGE2 and PGD2 . CONCLUSIONS AND IMPLICATIONS: These findings define mechanisms by which myofibroblasts enhance an AAM phenotype, which can promote wound healing directly, and/or via feedback communication to the myofibroblast, subsequently down-regulating its capacity to promote AAM function. This is an important homeostatic regulatory pathway in wound healing that can also limit unwanted fibrosis.
BACKGROUND AND PURPOSE: Alternatively activated macrophages (AAMs) are important cells in the resolution of inflammation and tissue repair. We examined the impact of myofibroblasts, a vital cell in wound healing and tissue repair, on the development and function of AAMs. EXPERIMENTAL APPROACH: The interaction between AAMs and myofibroblasts was tested using conditioned medium from murine dermal myofibroblasts and bone marrow-derived macrophages. AAMs were differentiated with IL-4 and IL-13. KEY RESULTS: Conditioned medium from myofibroblasts enhanced the expression of AAM markers, arginase 1 and Ym1 (chitinase-3-like 3) and the spontaneous production of IL-10, while suppressing LPS-induced nitric oxide production. IL-6 from the myofibroblasts contributed to the amplification of the AAM phenotype; the selective COX-2 inhibitor, NS-398, significantly reduced the ability of myofibroblasts to promote an AAM phenotype. Pharmacological analyses indicated that myofibroblast-derived IL-6 enhanced arginase activity and spontaneous IL-10 output, while PGE2 , via the EP4 receptor, enhanced arginase expression and LPS-evoked IL-10 production. PGD2 suppressed LPS-evoked nitric oxide via the DP1 receptor. Reciprocally, conditioned medium from macrophages treated with IL-4 + IL-13 and myofibroblast conditioned medium components, but not macrophages given IL-4 + IL-13 only, reduced myofibroblast migration, the expression of COX-2, and the production of PGE2 and PGD2 . CONCLUSIONS AND IMPLICATIONS: These findings define mechanisms by which myofibroblasts enhance an AAM phenotype, which can promote wound healing directly, and/or via feedback communication to the myofibroblast, subsequently down-regulating its capacity to promote AAM function. This is an important homeostatic regulatory pathway in wound healing that can also limit unwanted fibrosis.
Authors: Victoria Dimitriades; Paulo C Rodriguez; Jovanny Zabaleta; Augusto C Ochoa Journal: Ann Allergy Asthma Immunol Date: 2014-07-11 Impact factor: 6.347
Authors: Christopher D Buckley; Derek W Gilroy; Charles N Serhan; Brigitta Stockinger; Paul P Tak Journal: Nat Rev Immunol Date: 2012-11-30 Impact factor: 53.106
Authors: Claire E Witherel; Kimheak Sao; Becky K Brisson; Biao Han; Susan W Volk; Ryan J Petrie; Lin Han; Kara L Spiller Journal: Biomaterials Date: 2021-01-07 Impact factor: 12.479
Authors: Gillian A Gray; Christopher I White; Raphael F P Castellan; Sara J McSweeney; Karen E Chapman Journal: J Mol Endocrinol Date: 2016-08-23 Impact factor: 5.098
Authors: Jorge Arasa; María Carmen Terencio; Rosa María Andrés; Asunción Marín-Castejón; Francisca Valcuende-Cavero; Miguel Payá; María Carmen Montesinos Journal: Front Immunol Date: 2019-03-20 Impact factor: 7.561